Physician profile
Lorenzo Rossaro
NPI 1750368163
$184,692.99
in general payments reported to CMS, 2019-2025
15 companies · $75K in 2025
The $75K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.18 · 2022: $1,390 · 2023: $4,070 · 2024: $104K · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $155K · Travel and Lodging: $13K · Food and Beverage: $6,753 · Honoraria: $6,000 · Consulting Fee: $2,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $155,020.00 |
| Travel and Lodging | $12,981.76 |
| Food and Beverage | $6,752.68 |
| Honoraria | $6,000.00 |
| Consulting Fee | $2,480.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $124,065.76 | 2022-2025 | Terlivaz |
| Abbvie INC. | $48,638.36 | 2022-2025 | Mavyret |
| Intra-Sana Laboratories | $6,440.77 | 2024-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Ipsen Biopharmaceuticals, INC | $3,421.16 | 2024-2025 | Iqirvo |
| Gilead Sciences, INC. | $808.89 | 2022-2024 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $497.54 | 2022-2024 | Xifaxan, Plenvu |
| Madrigal Pharmaceuticals | $263.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Paragonix Technologies, INC. | $153.90 | 2024 | Baroguard, Lungguard, Liverguard |
| Intercept Pharmaceuticals, INC. | $107.74 | 2022-2024 | Ocaliva |
| Mirum Pharmaceuticals, INC. | $68.47 | 2024 | Livmarli |
| Biocompatibles, INC. | $68.18 | 2019 | |
| Orphalan INC | $51.20 | 2024 | Cuvrior |
| Histosonics, INC. | $46.47 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.02 | 2024 | Entyvio, Livtencity |
| Lucid Diagnostics INC. | $18.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorenzo Rossaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.